Agree Realty Corporation (ADC)
XMEX 
Summary
ADC Chart
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer
SAN FRANCISCO and SUZHOU, China , June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, updated the Phase 1 study results of IBI343, a novel anti-CLDN18.2 ADC, for the treatment of advanced pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. With extended follow-up and more mature data on progression-free survival (PFS) and overall survival (OS), IBI343 has demonstrated promising therapeutic efficacy in patients with CLDN18.2-positive advanced pancreatic cancer.
2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors
SAN FRANCISCO and SUZHOU, China , June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, updated the clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland , June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 107,550 of the Company's common shares to two new employees on June 2, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.
Agree Realty Corporation Dividends
| ADC 3 months ago Paid | Monthly | $0.25 Per Share |
| ADC 4 months ago Paid | Monthly | $0.25 Per Share |
| ADC 5 months ago Paid | Monthly | $0.25 Per Share |
| ADC 6 months ago Paid | Monthly | $0.25 Per Share |
| ADC 7 months ago Paid | Monthly | $0.25 Per Share |
Agree Realty Corporation Earnings
| 21 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 11 Feb 2025 Date | | 0.44 Cons. EPS | 0.41 EPS |
| 22 Oct 2024 Date | | 0.43 Cons. EPS | 0.42 EPS |
| 30 Jul 2024 Date | | 0.44 Cons. EPS | - EPS |
| ADC 3 months ago Paid | Monthly | $0.25 Per Share |
| ADC 4 months ago Paid | Monthly | $0.25 Per Share |
| ADC 5 months ago Paid | Monthly | $0.25 Per Share |
| ADC 6 months ago Paid | Monthly | $0.25 Per Share |
| ADC 7 months ago Paid | Monthly | $0.25 Per Share |
| 21 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 11 Feb 2025 Date | | 0.44 Cons. EPS | 0.41 EPS |
| 22 Oct 2024 Date | | 0.43 Cons. EPS | 0.42 EPS |
| 30 Jul 2024 Date | | 0.44 Cons. EPS | - EPS |
Agree Realty Corporation (ADC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Agree Realty Corporation ever had a stock split?
Agree Realty Corporation Profile
| REIT - Retail Industry | Real Estate Sector | Mr. Joel N. Agree J.D. CEO | XMEX Exchange | US0084921008 ISIN |
| US Country | 75 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Agree Realty Corporation is a distinguished Maryland corporation, operating as a fully integrated real estate investment trust (REIT). Since its establishment in 1971 by Richard Agree, who notably holds the position of Executive Chairman, the company has committed itself to the ownership, acquisition, development, and management of retail properties. These properties are primarily net leased to top-tier tenants, positioning the company as a leader in the retail real estate sector. The company’s shares have been publicly traded on the New York Stock Exchange since 1994, marking a significant milestone in its history. As of March 31, 2024, Agree Realty Corporation boasts ownership of 2,161 properties. This portfolio encompasses an impressive total gross leasable area (GLA) of approximately 44.9 million square feet, reflecting the company’s significant impact on the retail property market.
Products and Services
- Ownership of Retail Properties
- Acquisition of Retail Properties
- Development of Retail Properties
- Management of Retail Properties
Agree Realty Corporation holds an extensive portfolio of retail properties, which are strategically net leased to leading tenants across various industries. This facet of the business underscores their ability to cultivate and manage relationships with significant retail players, ensuring stable and long-term lease agreements.
The company actively engages in the acquisition of retail properties, with a keen focus on expanding its portfolio in alignment with strategic goals. Through careful selection, Agree Realty Corporation invests in properties that promise growth and sustainability, enhancing its investment value over time.
Beyond ownership and acquisition, Agree Realty Corporation is deeply involved in the development of retail properties. This includes the conceptualization and construction of new properties, along with the redevelopment of existing sites, ensuring they meet the evolving needs of tenants and the market.
The comprehensive management services offered by Agree Realty Corporation cover all aspects of property management. This involves operational oversight, maintenance, and enhancements, aimed at maximizing the performance and value of each property within the portfolio.
Contact Information
